A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma.
A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma.
复制标题
非转移性肛门鳞状细胞癌的临床和分子特征。
DOI：
10.1016/j.tranon.2021.101084
复制
发表时间：
2021-06
影响因子：
5
通讯作者：
Abba MC
中科院分区：
文献类型：
--
作者：
Iseas S;Golubicki M;Robbio J;Ruiz G;Guerra F;Mariani J;Salanova R;Cabanne A;Eleta M;Gonzalez JV;Basiletti J;Picconi MA;Masciangioli G;Carballido M;Roca E;Mendez G;Coraglio M;Abba MC
High-risk HPV infection is less frequently detected in HIV-positive non-metastatic ASCC compared with HIV-negative cases. Mutational profile identified in the non-metastatic ASCC cohort revealed expected similarities with metastatic ASCC. High PD-L1 expression levels are associated with high CD3 and CD8 TIL density, complete response to treatment, and good survival outcome of ASCC patients. PD-L1 is a reliable predictive and prognostic biomarker that allows the stratification in low- vs. high-risk ASCC patients at their initial therapeutic approach. Anal squamous cell carcinoma (ASCC) is a rare gastrointestinal malignancy associated with high-risk Human papillomavirus (HPV) infection. Despite improved outcomes in non-metastatic ASCC, definitive chemoradiotherapy constitutes the standard treatment for localized disease. Evidences for predictive and prognostic biomarkers are limited. Here, we performed a viral, immune, and mutational characterization of 79 non-metastatic ASCC patients with complete definitive chemoradiotherapy. HPV-16 was detected in 91% of positive cases in single infections (78%) or in coinfections with multiple genotypes (22%). Fifty-four percent of non-metastatic ASCC cases displayed mutations affecting cancer driver genes such as PIK3CA (21% of cases), TP53 (15%), FBXW7 (9%), and APC (6%). PD-L1 expression was detected in 57% of non-metastatic ASCC. Increased PD-L1 positive cases (67%) were detected in patients with complete response compared with non-complete response to treatment (37%) (p = 0.021). Furthermore, patients with PD-L1 positive tumors were significantly associated with better disease-free survival (DFS) and overall survival (OS) compared with patients with PD-L1 negative tumors (p = 0.006 and p = 0.002, respectively). PD-L1 expression strongly impacts CR rate and survival of non-metastatic ASCC patients after standard definitive chemoradiotherapy. PD-L1 expression could be used to stratify good versus poor responders avoiding the associated morbidity with abdominal perineal resection.
登录
查看更多内容
DOI：
10.1097/qad.0000000000000808
发表时间：
2015-10-23
期刊：
AIDS (London, England)
影响因子：
--
作者：
de Martel C;Shiels MS;Franceschi S;Simard EP;Vignat J;Hall HI;Engels EA;Plummer M
通讯作者：
Plummer M
影响因子：
6.4
作者：
de Martel C;Plummer M;Vignat J;Franceschi S
通讯作者：
Franceschi S
DOI：
10.1158/1541-7786.mcr-17-0060
发表时间：
2017-11
期刊：
Molecular cancer research : MCR
影响因子：
--
作者：
Morris V;Rao X;Pickering C;Foo WC;Rashid A;Eterovic K;Kim T;Chen K;Wang J;Shaw K;Eng C
通讯作者：
Eng C
影响因子：
8.8
作者：
Eklund, Carina;Forslund, Ola;Dillner, Joakim
通讯作者：
Dillner, Joakim
影响因子：
50.5
作者：
Glynne-Jones, R.;Nilsson, P. J.;Arnold, D.
通讯作者：
Arnold, D.